Addition of immunotherapy to perioperative cancer treatment linked to more toxicity

The addition of immunotherapy to perioperative conventional cancer therapy appeared linked to more grade 3 to grade 4 treatment related adverse events, according to findings published in The Lancet Oncology.
“Our study emphasizes the importance of safety evaluation among patients receiving immunotherapy before or after the curative treatment, which is usually surgery,” Yu Fujiwara, MD, a hematology/oncology fellow at Roswell Park Comprehensive Cancer Center, told Healio.
The use of immune checkpoint blockade as part of perioperative cancer therapy has improved outcomes; however,

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart